



## Review

## Cysteine string protein (CSP) and its role in preventing neurodegeneration



Robert D. Burgoyne, Alan Morgan\*

Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown St., Liverpool L69 3BX, UK

## ARTICLE INFO

## Article history:

Available online 21 March 2015

## Keywords:

DNAJC5  
 SNAREs  
 SNAP-25  
 Adult onset neuronal ceroid lipofuscinosis  
 Alzheimer's disease  
 Resveratrol

## ABSTRACT

Cysteine string protein (CSP) is a member of the DnaJ/Hsp40 family of co-chaperones that localises to neuronal synaptic vesicles. Its name derives from the possession of a string of 12–15 cysteine residues, palmitoylation of which is required for targeting to post-Golgi membranes. The DnaJ domain of CSP enables it to bind client proteins and recruit Hsc70 chaperones, thereby contributing to the maintenance of protein folding in the presynaptic compartment. Mutation of CSP in flies, worms and mice reduces lifespan and causes synaptic dysfunction and neurodegeneration. Furthermore, recent studies have revealed that the neurodegenerative disease, adult onset neuronal ceroid lipofuscinosis, is caused by mutations in the human CSP $\alpha$ -encoding *DNAJC5* gene. Accumulating evidence suggests that the major mechanism by which CSP prevents neurodegeneration is by maintaining the conformation of SNAP-25, thereby facilitating its entry into the membrane-fusing SNARE complex. In this review, we focus on the role of CSP in preventing neurodegeneration and discuss how recent studies of this universal neuroprotective chaperone are being translated into potential novel therapeutics for neurodegenerative diseases.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## Contents

1. Introduction: discovery and properties of CSPs .....	153
2. Which proteins are substrates for refolding by the synaptic chaperone CSP? .....	154
3. Cellular functions of CSP .....	154
4. CSP and neurodegeneration .....	154
5. CSP and human neurodegenerative disease .....	156
6. Therapeutic implications .....	156
7. Conclusions .....	157
Acknowledgements .....	157
References .....	157

## 1. Introduction: discovery and properties of CSPs

Cysteine string protein (CSP) was first discovered in *Drosophila melanogaster* based on the use of a neuronal-specific monoclonal antibody that labelled nerve terminals. Cloning of cDNA revealed

that the antibody recognised proteins encoded by three splice variants of a novel gene. These were distinguished by the presence of a string of 11 contiguous cysteine residues leading to the naming of the protein(s) as cysteine string protein [1]. Soon after, a CSP was also discovered in *Torpedo californica* following an attempt to identify possible subunits of neuronal calcium channels, which at that time had not been identified or molecularly characterised [2], and it was shown to be localised to synaptic vesicles [3]. CSPs were soon identified in mammalian species [4–6]. The *Torpedo* protein [7] and subsequently CSPs in other species were found to be extensively palmitoylated on their cysteine residues. Palmitoylation was shown to determine the membrane association of CSPs [8–10] and the enzymatic basis for palmitoylation of CSP has been extensively


**Abbreviations:** ANCL, adult onset neuronal ceroid lipofuscinosis; CREB, cAMP response element binding protein; CSP, cysteine string protein; GABA, gamma-amino butyric acid; SGT, small glutamine-rich tetratricopeptide repeat-containing protein; SNAP-25, synaptosome-associated protein of 25-kDa; SNAREs, soluble NSF attachment protein receptors; VAMP, vesicle associated membrane protein.

\* Corresponding author. Tel.: +44 151 794 5333; fax: +44 151 794 5337.

E-mail address: [amorgan@liverpool.ac.uk](mailto:amorgan@liverpool.ac.uk) (A. Morgan).

<http://dx.doi.org/10.1016/j.semcdb.2015.03.008>

1084-9521/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).



**Fig. 1.** Domain structure of human CSP $\alpha$ . The locations of the Serine10 phosphorylation site, the HPD motif in the J domain, and the cysteine-rich region of the protein are indicated. The leucine residues mutated in ANCL patients are highlighted by asterisks.

studied [11–16]. In addition to being expressed in multiple species, CSP was also found to be present on a wide range of types of secretory vesicles in neuronal and non-neuronal tissues [5,6,17–19]. Invertebrates such as *Drosophila* and *Caenorhabditis elegans* have only a single CSP-encoding gene (*Csp* and *dncj-14*, respectively); whereas mammals express three CSP proteins ( $\alpha$ ,  $\beta$ ,  $\gamma$ ) that are encoded by the *DNAJC5a*, *b* and *g* genes. CSP $\alpha$  and CSP $\beta$  are highly homologous throughout their amino acid sequences, but CSP $\gamma$  is more distantly related [20]. CSP $\alpha$  is the major protein expressed in most cells and virtually all neurons. In contrast, mammalian CSP $\beta$  and CSP $\gamma$  are expressed only in testis [21,22], with the exception that CSP $\beta$  is uniquely also expressed in auditory hair cell neurons [23,24]. The functional roles of CSP $\beta$  and CSP $\gamma$  are unknown.

The sequence of CSP revealed that it contains a conserved J domain (Fig. 1) and so it is a member of the DnaJ/Hsp40 family of co-chaperones. CSP has a characteristic HPD motif in the J-domain that is required in this family of proteins to allow them to bind to Hsc70/Hsp70 and act in concert with Hsc70/Hsp70 in the refolding or disaggregation of client proteins. Biochemical analysis of CSP demonstrated that it could indeed bind to and activate the ATPase activity of Hsc70 [25,26] and also that it could reverse aggregation of model substrates in conjunction with Hsc70 [27]. It was subsequently suggested that CSP and Hsc70 function along with small glutamine-rich tetratricopeptide repeat-containing protein (SGT) in a trimeric complex [28,29]. While CSP is clearly able to bind to SGT, there are doubts about the physiological significance of the SGT interaction. These stem from the fact that the interaction of SGT with CSP characterised in vitro with recombinant proteins and via the yeast 2-hybrid method occurs through the non-palmitoylated cysteine-string domain [29], which would not be available for interaction in vivo. Recently it has been established that SGT is a chaperone for the transmembrane region of tail-anchored proteins [30,31], suggesting that SGT binding to recombinant CSP in vitro may be a consequence of its artefactual recognition of the hydrophobic cysteine rich region due to its similarity to a bona fide transmembrane domain.

## 2. Which proteins are substrates for refolding by the synaptic chaperone CSP?

Early efforts to discover potential clients for CSP identified multiple direct protein interactions including with syntaxin [32–34], VAMP [35,36], G protein subunits [37,38], Rab-GDI [39], mutant huntingtin [40,41], the  $\alpha$ 1B subunit of N-type calcium channels [37,42], the  $\alpha$ 1A subunit of P/Q type calcium channels [43] and synaptotagmins [44,45]. The observed reduction of SNAP-25 in CSP $\alpha$  knock out mice led to the identification of this protein as a potential CSP $\alpha$  client [46]. More recent work has attempted to identify novel CSP $\alpha$  clients by using an unbiased proteomic approach searching for any proteins down-regulated in the brains of CSP $\alpha$  knock-out mice. This resulted in the identification of 10 chaperones and 27 additional down-regulated proteins that included SNAP-25 [47]. The identification of one novel CSP $\alpha$  client, dynamin 1, was confirmed in direct binding assays and a role for CSP $\alpha$  in

dynamin-mediated synaptic vesicle recycling was described in another study [48].

## 3. Cellular functions of CSP

Information on the functional importance of CSP came initially from analysis of *Csp* mutants in *Drosophila*. The first of the papers on these mutants provided key evidence supporting the now accepted role of CSP as a neuroprotective chaperone at the synapse [49–51]. In this work it was found that loss of CSP expression resulted in very rapid death of adult flies, by 5 days at 22 °C and within 1 h at 29 °C, and the flies showed evidence of synaptic degeneration observed by electron microscopy [52]. The follow-up analyses of these mutant flies focused to a large extent on studying the phenotype of the few adult survivors (95% of *Csp* null mutants die during development) and in particular there was an emphasis on what was seen as the “temperature-dependent” aspects of the phenotypes, where the flies rapidly became paralysed at elevated temperature [53], rather than the causes of the rapid neurodegeneration and death.

Electrophysiological analysis of synaptic function in *Csp* mutant flies suggested that CSP was required for normal synchronous evoked neurotransmitter release [54,55], but this did not appear to be related to any effect on presynaptic calcium channel function [56]. In addition, the flies showed various defects in calcium handling or calcium coupling to exocytosis [57–60]. Studies on non-neuronal cells, examining the effects of CSP overexpression suggested a direct role for CSP in regulated exocytosis [61–64]. The ability of CSP to interact with its client proteins syntaxin or synaptotagmin in vitro was found to be modulated by its phosphorylation on Serine10 [44,65] and this phosphorylation allows interaction of CSP with 14-3-3 protein [66]. Ser10 phosphorylation on CSP appears to be constitutive within neuronal tissues [67–69], although the extent of phosphorylation varies greatly between neighbouring GABAergic and glutamatergic synapses within the same region of the cerebellum [67]. The effects of CSP overexpression on the late stages of regulated exocytosis are modulated by its phosphorylation on Ser10 [65,70,71].

## 4. CSP and neurodegeneration


The key neuroprotective role of CSP was apparent in the fly mutants but only rose to prominence in considerations of the function of the protein following analysis of CSP $\alpha$  knock-out mice. For the first few weeks of life, these mice appeared normal and did not show defects in neurotransmission [22], but then developed a progressive sensorimotor disorder, evidence of neurodegeneration in neuromuscular junctions and calyx synapses and died at around 8 weeks of age. These mice also showed extensive and rapid degeneration of retinal photoreceptors [23] and hippocampal GABAergic neurons were found to be differentially sensitive to the absence of CSP $\alpha$  compared to glutamatergic neurons [72]. The high sensitivity of GABAergic neurons was attributed to their high levels of synaptic activity, which is consistent with the more rapid degeneration seen in tonically active ribbon synapses of photoreceptor cells

compared to other retinal synapses [23]. More detailed analysis of the mice revealed additional defects in synaptic function including a reduction in the normal calcium sensitivity of the neurotransmitter release mechanism [73] and also an impairment of synaptic vesicle recycling at the neuromuscular junction [48]. These latter findings would fit with the existence of multiple client proteins for CSP including dynamin 1.

The evolutionary conservation of CSP's neuroprotective function is underlined by a recent study of the *C. elegans* CSP orthologue, which is known as DNJ-14. The phenotypes of *dnj-14* null mutant worms show remarkable similarities to CSP knockout mice in that young animals are virtually indistinguishable from wild-type, but exhibit progressive neuronal dysfunction and neurodegeneration with increasing age and have a reduced lifespan [24]. It is not clear why complete loss of CSP in *Drosophila* causes ~95% embryonic lethality, whereas no major effects on fertility or initial viability are observed in knockout worms and mice, but perhaps this reflects some specific functions of CSP during fly development. Neurodegeneration in aged *C. elegans dnj-14* mutants preferentially affects sensory neurons and indeed these animals exhibit severely impaired chemosensory neuron function before neurodegeneration becomes apparent [24]. This progression from early functional synaptic defects leading on to later structural alterations and neuronal death is reminiscent of many neurodegenerative diseases and suggests that the *dnj-14* worm model may be useful for identifying generally neuroprotective mechanisms and therapies. However, the surprising observation that loss of CSP is actually neuroprotective in a *Drosophila* model of injury-induced axonal degeneration [74] suggests that some acute neurodegeneration models could involve distinct mechanisms that may not be ameliorated by CSP's otherwise universal neuroprotective function.

A surprising finding was that the neurodegeneration and reduced life-span in CSP $\alpha$  KO mice was significantly reversed by overexpressing  $\alpha$ -synuclein [46]. Both wild-type and a disease-related mutant (A30P)  $\alpha$ -synuclein had positive effects although that of the wild-type protein was more marked. Conversely, the CSP $\alpha$  KO phenotype was exacerbated by knock-out of  $\alpha$ - or  $\beta$ -synuclein [46]. Analysis of CSP $\alpha$  KO mice expressing the A30P mutant version of  $\alpha$ -synuclein revealed that these mice show increased synaptic function consistent with a protective function even of this pathogenic form of  $\alpha$ -synuclein [75]. A further important observation from the study of CSP $\alpha$  KO mice and  $\alpha$ -synuclein overexpression was that the absence of CSP $\alpha$  resulted in a reduction in SNAP-25 levels and a corresponding reduction in the levels of assembled SNARE complexes [46]. The loss of SNAP-25 was not affected by overexpression of  $\alpha$ -synuclein. In contrast, wild type but not A30P  $\alpha$ -synuclein reversed the reduction in SNARE complexes suggesting that this may contribute, at least in part, to the protective effect of  $\alpha$ -synuclein. A further link between  $\alpha$ -synuclein and CSP $\alpha$  was shown in a study examining the effects of exogenous  $\alpha$ -synuclein or a  $\beta$ -amyloid peptide on cultured hippocampal neurons where both treatments were observed to result in a reduction in levels of CSP $\alpha$  expression [76].

It may seem surprising that SNAP-25 has been identified as a potential client for CSP $\alpha$ , as CSP $\alpha$  is primarily a synaptic vesicle protein whereas SNAP-25 is largely localised to the axonal plasma membrane (Fig. 2). Furthermore, CSP $\alpha$  is expressed at relatively low levels (2.8 molecules per synaptic vesicle and 941 molecules per synapse, on average) compared to the very abundant SNAP-25 (26,686 molecules per synapse) [77,78]. This raises some interesting mechanistic questions, as presumably only SNAP-25 molecules in the immediate proximity of tethered/docked vesicles at the active zone would be close enough to be chaperoned by CSP $\alpha$ /Hsc70. Perhaps this forms a useful checkpoint system, ensuring that the energy of ATP hydrolysis by Hsc70 is only expended on priming SNAP-25 molecules that can form a local SNARE complex



**Fig. 2.** Chaperoning of SNAP-25 by CSP and Hsc70 at the synapse. A typical synaptic vesicle containing approximately three molecules of CSP [77] is represented. Binding of Hsc70 to SNAP-25 is thought to recruit CSP, thereby altering the conformation of SNAP-25, facilitating its entry onto the SNARE complex that drives membrane fusion. Direct binding is indicated by double-headed arrows. Structures of SNAP-25 (3IPD), and hsc70/DnaK (2KHO) were obtained from the Brookhaven protein data bank. The CSP structure prediction was generated by I-TASSER. Residues involved in Hsc70 binding (HPD motif, blue), synaptotagmin binding (E93, yellow), and the serine-10 phosphorylation site (green) are highlighted as spheres. All structures were rendered using UCSF chimera.

and so drive membrane fusion. Nevertheless, it remains unclear how CSP prevents proteasomal degradation of the majority of the cellular pool of SNAP-25 despite its substrate being >25-fold in excess and mostly localised away from the active zone where CSP binding could potentially occur.

Notwithstanding these questions, detailed analysis of the CSP $\alpha$  knock-out mice has strongly suggested that SNAP-25 is the major client for CSP, that CSP $\alpha$  stimulates SNARE complex assembly and that neurodegeneration in the absence of CSP $\alpha$  can be explained by defective SNAP-25 function [79,80]. The work of Sharma et al. [79] showed that in the absence of CSP $\alpha$  SNAP-25 is selectively decreased due to its ubiquitination and its proteolysis in an activity-dependent manner. Moreover, CSP $\alpha$  over-expression increased SNAP-25 levels. In vitro binding experiments suggested that CSP $\alpha$  did not bind directly to SNAP-25, but did so indirectly via Hsc70. This is unusual as J domain proteins usually bind the client protein directly and then subsequently recruit Hsc70. In an additional study exploring synuclein function it was found that the absence of the synucleins reduced the ability of the SNAREs to assemble into SNARE complexes and that  $\alpha$ -synuclein directly stimulated SNARE complex assembly in vitro. This required the direct binding of  $\alpha$ -synuclein to VAMP. These findings could explain the earlier finding [46] that over-expression of  $\alpha$ -synuclein compensates for the loss of CSP $\alpha$  and thereby SNAP-25. A key question at this point was whether the effect of CSP $\alpha$  absence on SNAP-25 levels or on its folding is the cause of neurodegeneration in the CSP $\alpha$  knock-out mice. One possibility was that it is not the reduction in SNAP-25 levels themselves that leads to synaptic dysfunction and subsequent neurodegeneration, but the accumulation of aberrantly folded forms of SNAP-25 that undergo abnormal protein interactions or that other CSP $\alpha$  clients were involved [81]. This issue of the link between SNAP-25 and neurodegeneration was further addressed leading to the finding that decreased SNAP-25 levels worsened the CSP $\alpha$  knock-out

phenotype reducing life-span and levels of assembled SNARE complexes and exacerbated neurodegeneration [80]. An increase of SNAP-25 levels using lentiviral expression rescued the CSP $\alpha$  knock-out phenotype with neurodegeneration (neuronal loss) being reversed in brain regions over-expressing SNAP-25. These findings are consistent with SNAP-25 being the main CSP $\alpha$  client whose loss leads to neurodegeneration in the absence of CSP $\alpha$ .

## 5. CSP and human neurodegenerative disease

Despite the compelling evidence for an essential role of CSP in preventing neurodegeneration in animal models, a direct link to human disease was established only recently. Between 2011 and 2013, four independent research groups reported an association between mutations in the CSP $\alpha$ -encoding *DNAJC5* gene and adult onset neuronal ceroid lipofuscinosis (ANCL), using a combination of whole exome sequencing, linkage analysis and candidate gene resequencing [82–85]. ANCL, also known as autosomal dominant Kufs' disease and Parry disease, is a very rare hereditary neurodegenerative disorder. It presents with broad clinical variability, although common signs include generalised epilepsy, movement disorders and progressive dementia. The disease has a mean age of onset of 30 years and progresses rapidly upon diagnosis, with death occurring on average at 45 years of age [85]. Pathologically, ANCL is associated with intra-neuronal inclusions of autofluorescent lipofuscin-like material and neurodegeneration, hence its classification as one of the neuronal ceroid lipofuscinoses, which is a large genetically heterogeneous class of neurodegenerative disorders defined by these two essential features [86,87]. However, the visual system tends to be unaffected by neurodegeneration in ANCL, in contrast to most other NCLs that are generally associated with blindness [85,86]. Given its rarity and clinical variability, ANCL is often misdiagnosed [83], so it is important that several independent groups identified the same *DNAJC5* mutations in different patient groups, leaving little doubt that these mutations cause ANCL.

Interestingly, all ANCL patients studied to date harbour one of two mutations in the coding sequence for the cysteine string motif, resulting in either a deletion of leucine116 or a leucine115-arginine substitution [82–85] (see Fig. 1). Given the known requirement of the cysteine string domain for palmitoylation [7,9,10] and for targeting to post-Golgi membranes [9], this immediately suggested that the mutant proteins may be inefficiently targeted to synaptic vesicles. Indeed, the original report by Noskova et al. [82] showed that recombinant GFP-tagged CSP $\alpha$  mutant constructs were retained in an abnormal cell body localisation co-migrating with endoplasmic reticulum and Golgi markers, in contrast to wild type GFP-CSP $\alpha$  that was efficiently transported to the plasma membrane. Consistent with such a targeting defect, post-mortem brain samples from ANCL patients similarly showed a large reduction in synaptic CSP $\alpha$  levels compared to controls [82]. These findings were independently confirmed and extended by Greaves et al. [88], who demonstrated that the ANCL mutations induce aggregation into SDS-resistant palmitoylated aggregates. Importantly, Greaves et al. used a dual epitope tagging system to reveal that wild type CSP $\alpha$  can co-aggregate with mutant CSP $\alpha$  [88], a finding that has recently been confirmed [89], thereby potentially explaining the dominant effect of the mutations and the otherwise puzzling observation that ANCL patients lack synaptic CSP $\alpha$  protein despite carrying one wild type *DNAJC5* allele.

Although ANCL is the only disease known to be caused by CSP mutations, alterations in the levels or activity of CSP could potentially impact on other neurodegenerative conditions given its neuroprotective function. One clue is the finding that CSP $\alpha$  can interact with mutant huntingtin containing an expanded polyQ domain but not the wild type protein in vitro [40]. This was confirmed in a proteomic study of mouse brain [41] but its relevance


to the progress of Huntington's disease is still to be established. In addition, it has recently been reported that expression of CSP $\alpha$  is reduced in degenerating areas of the forebrain in post-mortem samples of Alzheimer's patients [90]. It appears that this is not simply a consequence of reduced synaptic vesicle number, as the integral synaptic membrane protein marker, synaptophysin, did not exhibit equivalent reduced expression. Interestingly, the reduction of CSP $\alpha$  expression is restricted to degenerating brain areas, with levels actually being increased in non-degenerating cerebellar tissue from the same patients [90]. Note, however, that heterozygous CSP KO mice, which contain half the normal CSP protein level, do not show any difference in susceptibility to prion disease in the ME7 model [91]. Nevertheless, a further connection between CSP $\alpha$  and more common forms of neurodegeneration comes from the observation that SNARE complex levels are reduced in post-mortem brain samples from both Alzheimer's and Parkinson's disease patients [92]. Given the role of CSP $\alpha$  in facilitating SNARE complex assembly discussed earlier, it is tempting to speculate that the reduced levels of SNARE complexes are a consequence of impaired CSP $\alpha$  chaperone activity. Clearly, it is important that further studies of post-mortem tissue from a variety of neurodegenerative diseases are performed to establish if altered CSP activity and/or SNARE complex assembly represent common underlying features of neurodegeneration.

## 6. Therapeutic implications

CSP is expressed in all synapses and prevents neurodegeneration in worms, flies, mice and humans. It therefore appears to be a generally neuroprotective chaperone protein. Drugs that could either increase CSP activity or bypass the requirement for CSP thus represent potential therapies – not only for ANCL, but also more generally for neurodegenerative diseases. Indeed, recent work has begun to identify compounds that can compensate for the lack of functional CSP in animal models. Treatment of CSP $\alpha$  knock-out mice with proteasome inhibitors was found to result in increased life-span and a delay in neurodegeneration [92]. This striking result is at first glance surprising, as one widely proposed therapeutic strategy for protein misfolding disorders that lead to neurodegeneration is to increase the activity of the ubiquitin-proteasome system that degrades the misfolded protein(s). It might be expected, therefore, that proteasome inhibition would exacerbate neurodegeneration in CSP $\alpha$  knock-out mice. The fact that the reverse is true was attributed to an observed increase in SNAP-25 levels and in assembled SNARE complexes through prevention of SNAP-25 degradation by the proteasome [92]. Furthermore, Sharma et al. showed that the reduced levels of assembled SNARE complexes that ultimately cause neurodegeneration in CSP $\alpha$  knock-out mice are also evident in post-mortem brain samples from Alzheimer's and Parkinson's disease patients [92]. Proteasome inhibitors may therefore have therapeutic applications for these common neurodegenerative diseases as well as for ANCL.

A recent chemical screen revealed that resveratrol can rescue the short lifespan, chemosensory impairment and neurodegeneration phenotypes of *C. elegans dnj-14* null mutants [24]. Resveratrol is a plant-derived polyphenolic compound found in various foodstuffs, notably red wine, which has well-documented cardio-protective, anti-inflammatory, anti-tumour and neuroprotective properties [93]. Its mechanism of action is the subject of considerable debate, although most attention has focused on resveratrol's ability to activate the Sirtuin class of NAD<sup>+</sup>-dependent histone deacetylases, notably SIRT1. However, rescue of the *dnj-14* phenotypes by resveratrol was unaffected by deletion of the worm SIRT1 orthologue, *sir-2.1*, suggesting a Sirtuin-independent mechanism





**Fig. 3.** Resveratrol and rolipram rescue the short lifespan of *C. elegans dnj-14* mutants. Lifespan assays were performed on *dnj-14(m3223)* strains, which contain a large deletion in the worm orthologue of CSP, in the presence and absence of drugs; and also on the corresponding wild type strain (Bristol N2).

of action. It has been suggested that resveratrol is a competitive inhibitor of cAMP phosphodiesterases [94]. This is consistent with the observation that rolipram (a structurally unrelated cAMP phosphodiesterase inhibitor with neuroprotective properties [95,96]) similarly rescued *dnj-14* phenotypes (Fig. 3) [24]. Furthermore, forskolin, which increases cAMP levels via activation of adenylate cyclase rather than phosphodiesterase inhibition, ameliorates the neuromuscular transmission defects in CSP $\alpha$  knock-out mice [48]. It is tempting to speculate that increased cAMP signalling activates alternative CSP-independent pathways that facilitate SNARE complex formation, thereby compensating for the lack of CSP in these animal models. Indeed, phosphorylation of SNAP-25 and other synaptic exocytosis proteins by cAMP-dependent protein kinase is known to increase SNARE-dependent neurotransmission [97,98]. Alternatively, it may be that cAMP acts via longer term changes in gene expression mediated by neuroprotective transcription factors such as cAMP response element binding protein (CREB) [99]. Given the recent observations of reduced levels of CSP [90] and of SNARE complexes [92] in Alzheimer's brain samples, this may be relevant to the reported therapeutic effects of rolipram [95] and resveratrol [100] in rodent Alzheimer's models.

## 7. Conclusions

Despite being discovered over 20 years ago, interest in CSP has increased greatly in recent years as a result of compelling evidence that it provides a universal neuroprotective role at synapses from worms to humans. The major mechanism by which CSP prevents neurodegeneration appears to be maintaining the conformation of SNAP-25 and thereby facilitating correct SNARE complex formation. However, we currently lack a molecular level description of how CSP and Hsc70 interact with SNAP-25, how this alters SNAP-25's conformation to facilitate SNARE complex formation, and how this interaction (which presumably can only occur in close proximity to the very small number of docked synaptic vesicles at the active zone) manages to prevent global degradation of SNAP-25 that mainly localises away from this region. In addition it seems likely that other client proteins, including dynamin, are also involved, so future genetic and proteomic studies may illuminate such SNAP-25-independent functions of CSP. To date, mutations in the *DNAJC5* gene encoding CSP $\alpha$  have only been associated with ANCL, but given the alterations in CSP and SNARE complex levels in Alzheimer's disease, future human genetic studies may well

reveal additional mutations/polymorphisms associated with other more common neurodegenerative disorders. Finally, the few studies reported so far demonstrate that it is possible to compensate for the lack of CSP with small molecules – further work in this area may enable translation of the basic research on CSP performed over the last 20 years into novel therapies for neurodegeneration.

## Acknowledgements

RDB and AM are grateful to the BBSRC, Wellcome Trust, MRC and AgeUK for funding their research into CSP over many years. The data presented in Fig. 3 are courtesy of Sudhanva Kahyap.

## References

- [1] Zinsmaier KE, Hofbauer A, Heimbeck G, Pflugfelder GO, Buchner S, Buchner E. A cysteine-string protein is expressed in retina and brain of *Drosophila*. *J Neurogenet* 1990;7:15–29.
- [2] Gunderson CB, Umbach JA. Suppression cloning of the cDNA for a candidate subunit of a presynaptic calcium channel. *Neuron* 1992;9:527–37.
- [3] Mastrogiacomo A, Parsons SM, Zampighi GA, Jenden DJ, Umbach JA, Gunderson CB. Cysteine string proteins: a potential link between synaptic vesicles and presynaptic Ca<sup>2+</sup> channels. *Science* 1994;263:981–2.
- [4] Mastrogiacomo A, Gunderson CB. The nucleotide and deduced amino acid sequence of a rat cysteine string protein. *Brain Res Mol Brain Res* 1995;28:12–8.
- [5] Chamberlain LH, Burgoyne RD. Identification of a novel cysteine string protein variant and expression of cysteine string proteins in non-neuronal cells. *J Biol Chem* 1996;271:7320–3.
- [6] Coppola T, Gunderson C. Widespread expression of human cysteine string proteins. *FEBS Lett* 1996;391:269–72.
- [7] Gunderson CB, Mastrogiacomo A, Faull K, Umbach JA. Extensive lipidation of a Torpedo cysteine string protein. *J Biol Chem* 1994;269:19197–9.
- [8] Gunderson CB, Umbach JA, Mastrogiacomo A. Cysteine-string proteins: a cycle of acylation and deacylation. *Life Sci* 1996;58:2037–40.
- [9] Chamberlain LH, Burgoyne RD. The cysteine-string domain of the secretory vesicle cysteine-string protein is required for membrane targeting. *Biochem J* 1998;335(Pt 2):205–9.
- [10] van de Goor J, Kelly RB. Association of *Drosophila* cysteine string proteins with membranes. *FEBS Lett* 1996;380:251–6.
- [11] Greaves J, Chamberlain LH. Dual role of the cysteine-string domain in membrane binding and palmitoylation-dependent sorting of the molecular chaperone cysteine-string protein. *Mol Biol Cell* 2006;17:4748–59.
- [12] Greaves J, Salaun C, Fukata Y, Fukata M, Chamberlain LH. Palmitoylation and membrane interactions of the neuroprotective chaperone cysteine-string protein. *J Biol Chem* 2008;283:25014–26.
- [13] Gorleku OA, Barns AM, Prescott GR, Greaves J, Chamberlain LH. Endoplasmic reticulum localization of DHHC palmitoyltransferases mediated by lysine-based sorting signals. *J Biol Chem* 2011;286:39573–84.
- [14] Lemonidis K, Gorleku OA, Sanchez-Perez MC, Grefen C, Chamberlain LH. The Golgi S-acylation machinery comprises ZDHHC enzymes with major differences in substrate affinity and S-acylation activity. *Mol Biol Cell* 2014;25:3870–83.
- [15] Stowers RS, Isacoff EY. *Drosophila* huntingtin-interacting protein 14 is a presynaptic protein required for photoreceptor synaptic transmission and expression of the palmitoylated proteins synaptosome-associated protein 25 and cysteine string protein. *J Neurosci* 2007;27:12874–83.
- [16] Ohyama T, Verstreken P, Ly CV, Rosenmund T, Rajan A, Tien AC, et al. Huntingtin-interacting protein 14, a palmitoyl transferase required for exocytosis and targeting of CSP to synaptic vesicles. *J Cell Biol* 2007;179:1481–96.
- [17] Braun JE, Scheller RH. Cysteine string protein, a DnaJ family member, is present on diverse secretory vesicles. *Neuropharmacology* 1995;34:1361–9.
- [18] Chamberlain LH, Henry J, Burgoyne RD. Cysteine string proteins are associated with chromaffin granules. *J Biol Chem* 1996;271:19514–7.
- [19] Pupier S, Leveque C, Marqueze B, Kataoka M, Takahashi M, Seagar MJ. Cysteine string proteins associated with secretory granules of the rat neurohypophysis. *J Neurosci* 1997;17:2722–7.
- [20] Evans GJ, Morgan A, Burgoyne RD. Tying everything together: the multiple roles of cysteine string protein (CSP) in regulated exocytosis. *Traffic* 2003;4:653–9.
- [21] Gorleku OA, Chamberlain LH. Palmitoylation and testis-enriched expression of the cysteine-string protein beta isoform. *Biochemistry* 2010;49:5308–13.
- [22] Fernandez-Chacon R, Wolfel M, Nishimune H, Tabares L, Schmitz F, Castellano-Munoz M, et al. The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. *Neuron* 2004;42:237–51.
- [23] Schmitz F, Tabares L, Khimich D, Strenzke N, de la Villa-Polo P, Castellano-Munoz M, et al. CSPalpha-deficiency causes massive and rapid photoreceptor degeneration. *Proc Natl Acad Sci U S A* 2006;103:2926–31.
- [24] Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, et al. *Caenorhabditis elegans dnj-14*, the orthologue of the *DNAJC5* gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for

- neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol. *Hum Mol Genet* 2014;23:5916–27.
- [25] Braun JE, Wilbanks SM, Scheller RH. The cysteine string secretory vesicle protein activates Hsc70 ATPase. *J Biol Chem* 1996;271:25989–93.
- [26] Chamberlain LH, Burgoyne RD. Activation of the ATPase activity of heat-shock proteins Hsc70/Hsp70 by cysteine-string protein. *Biochem J* 1997;322(Pt 3):853–8.
- [27] Chamberlain LH, Burgoyne RD. The molecular chaperone function of the secretory vesicle cysteine string proteins. *J Biol Chem* 1997;272:31420–6.
- [28] Tobaben S, Thakur P, Fernandez-Chacon R, Sudhof TC, Rettig J, Stahl B. A trimeric protein complex functions as a synaptic chaperone machine. *Neuron* 2001;31:987–99.
- [29] Tobaben S, Varoqueaux F, Brose N, Stahl B, Meyer G. A brain-specific isoform of small glutamine-rich tetratricopeptide repeat-containing protein binds to Hsc70 and the cysteine string protein. *J Biol Chem* 2003;278:38376–83.
- [30] Hecznicki P, High S. SGTA antagonizes BAG6-mediated protein triage. *Proc Natl Acad Sci U S A* 2012;109:19214–9.
- [31] Wang F, Brown EC, Mak G, Zhuang J, Denic V. A chaperone cascade sorts proteins for posttranslational membrane insertion into the endoplasmic reticulum. *Mol Cell* 2010;40:159–71.
- [32] Nie Z, Ranjan R, Wenniger JJ, Hong SN, Bronk P, Zinsmaier KE. Overexpression of cysteine-string proteins in *Drosophila* reveals interactions with syntaxin. *J Neurosci* 1999;19:10270–9.
- [33] Wu MN, Fergestad T, Lloyd TE, He Y, Brodie K, Bellen HJ. Syntaxin 1A interacts with multiple exocytic proteins to regulate neurotransmitter release in vivo. *Neuron* 1999;23:593–605.
- [34] Chamberlain LH, Graham ME, Kane S, Jackson JL, Maier VH, Burgoyne RD, et al. The synaptic vesicle protein, cysteine-string protein, is associated with the plasma membrane in 3T3-L1 adipocytes and interacts with syntaxin 4. *J Cell Sci* 2001;114:445–55.
- [35] Seagar M, Leveque C, Charvin N, Marquez B, Martin-Moutot N, Boudier JA, et al. Interactions between proteins implicated in exocytosis and voltage-gated calcium channels. *Philos Trans R Soc Lond B Biol Sci* 1999;354:289–97.
- [36] Boal F, Zhang H, Tessier C, Scotti P, Lang J. The variable C-terminus of cysteine string proteins modulates exocytosis and protein–protein interactions. *Biochemistry* 2004;43:16212–23.
- [37] Magga JM, Jarvis SE, Arnot MI, Zamponi GW, Braun JE. Cysteine string protein regulates G protein modulation of N-type calcium channels. *Neuron* 2000;28:195–204.
- [38] Natochin M, Campbell TN, Barren B, Miller LC, Hameed S, Artemyev NO, et al. Characterization of the G alpha(s) regulator cysteine string protein. *J Biol Chem* 2005;280:30236–41.
- [39] Sakisaka T, Meerlo T, Matteson J, Plutner H, Balch WE. Rab-alphaGDI activity is regulated by a Hsp90 chaperone complex. *EMBO J* 2002;21:6125–35.
- [40] Miller LC, Swayne LA, Chen L, Feng ZP, Wacker JL, Muchowski PJ, et al. Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin. *J Biol Chem* 2003;278:53072–81.
- [41] Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, Geschwind DH, et al. Network organization of the huntingtin proteomic interactome in mammalian brain. *Neuron* 2012;75:41–57.
- [42] Miller LC, Swayne LA, Kay JG, Feng ZP, Jarvis SE, Zamponi GW, et al. Molecular determinants of cysteine string protein modulation of N-type calcium channels. *J Cell Sci* 2003;116:2967–74.
- [43] Leveque C, Pupier S, Marquez B, Geslin L, Kataoka M, Takahashi M, et al. Interaction of cysteine string proteins with the alpha1A subunit of the P/Q-type calcium channel. *J Biol Chem* 1998;273:13488–92.
- [44] Evans GJ, Morgan A. Phosphorylation-dependent interaction of the synaptic vesicle proteins cysteine string protein and synaptotagmin I. *Biochem J* 2002;364:343–7.
- [45] Boal F, Laguerre M, Milochau A, Lang J, Scotti PA. A charged prominence in the linker domain of the cysteine-string protein Cspalpha mediates its regulated interaction with the calcium sensor synaptotagmin 9 during exocytosis. *FASEB J* 2011;25:132–43.
- [46] Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. *Cell* 2005;123:383–96.
- [47] Zhang YQ, Henderson MX, Colangelo CM, Ginsberg SD, Bruce C, Wu T, et al. Identification of CSPalpha clients reveals a role in dynamin 1 regulation. *Neuron* 2012;74:136–50.
- [48] Rozas JL, Gomez-Sanchez L, Mircheski J, Linares-Clemente P, Nieto-Gonzalez JL, Vazquez ME, et al. Motoneurons require cysteine string protein-alpha to maintain the readily releasable vesicular pool and synaptic vesicle recycling. *Neuron* 2012;74:151–65.
- [49] Chamberlain LH, Burgoyne RD. Cysteine-string protein: the chaperone at the synapse. *J Neurochem* 2000;74:1781–9.
- [50] Zinsmaier KE. Cysteine-string protein's neuroprotective role. *J Neurogenet* 2010;24:120–32.
- [51] Johnson JN, Ahrendt E, Braun JE. CSPalpha: the neuroprotective J protein. *Biochem Cell Biol* 2010;88:157–65.
- [52] Zinsmaier KE, Eberle KK, Buchner E, Walter N, Benzer S. Paralysis and early death in cysteine string protein mutants of *Drosophila*. *Science* 1994;263:977–80.
- [53] Umbach JA, Zinsmaier KE, Eberle KK, Buchner E, Benzer S, Gunderson CB. Presynaptic dysfunction in *Drosophila* csp mutants. *Neuron* 1994;13:899–907.
- [54] Heckmann M, Adelsberger H, Dudel J. Evoked transmitter release at neuromuscular junctions in wild type and cysteine string protein null mutant larvae of *Drosophila*. *Neurosci Lett* 1997;228:167–70.
- [55] Umbach JA, Gunderson CB. Evidence that cysteine string proteins regulate an early step in the Ca<sup>2+</sup>-dependent secretion of neurotransmitter at *Drosophila* neuromuscular junctions. *J Neurosci* 1997;17:7203–9.
- [56] Morales M, Ferrus A, Martinez-Padron M. Presynaptic calcium-channel currents in normal and csp mutant *Drosophila* peptidergic terminals. *Eur J Neurosci* 1999;11:1818–26.
- [57] Ranjan R, Bronk P, Zinsmaier KE. Cysteine string protein is required for calcium secretion coupling of evoked neurotransmission in *Drosophila* but not for vesicle recycling. *J Neurosci* 1998;18:956–64.
- [58] Umbach JA, Saitoe M, Kidokoro Y, Gunderson CB. Attenuated influx of calcium ions at nerve endings of csp and shibire mutant *Drosophila*. *J Neurosci* 1998;18:3233–40.
- [59] Dawson-Scully K, Bronk P, Atwood HL, Zinsmaier KE. Cysteine-string protein increases the calcium sensitivity of neurotransmitter exocytosis in *Drosophila*. *J Neurosci* 2000;20:6039–47.
- [60] Bronk P, Nie Z, Klose MK, Dawson-Scully K, Zhang J, Robertson RM, et al. The multiple functions of cysteine-string protein analyzed at *Drosophila* nerve terminals. *J Neurosci* 2005;25:2204–14.
- [61] Brown H, Larsson O, Branstrom R, Yang SN, Leibiger B, Leibiger I, et al. Cysteine string protein (CSP) is an insulin secretory granule-associated protein regulating beta-cell exocytosis. *EMBO J* 1998;17:5048–58.
- [62] Chamberlain LH, Burgoyne RD. Cysteine string protein functions directly in regulated exocytosis. *Mol Biol Cell* 1998;9:2259–67.
- [63] Zhang H, Kelley WL, Chamberlain LH, Burgoyne RD, Wollheim CB, Lang J. Cysteine-string proteins regulate exocytosis of insulin independent from transmembrane ion fluxes. *FEBS Lett* 1998;437:267–72.
- [64] Graham ME, Burgoyne RD. Comparison of cysteine string protein (Csp) and mutant alpha-SNAP overexpression reveals a role for csp in late steps of membrane fusion in dense-core granule exocytosis in adrenal chromaffin cells. *J Neurosci* 2000;20:1281–9.
- [65] Evans GJ, Wilkinson MC, Graham ME, Turner KM, Chamberlain LH, Burgoyne RD, et al. Phosphorylation of cysteine string protein by protein kinase A. Implications for the modulation of exocytosis. *J Biol Chem* 2001;276:47877–85.
- [66] Prescott GR, Jenkins RE, Walsh CM, Morgan A. Phosphorylation of cysteine string protein on Serine 10 triggers 14-3-3 protein binding. *Biochem Biophys Res Commun* 2008;377:809–14.
- [67] Evans GJ, Morgan A. Phosphorylation of cysteine string protein in the brain: developmental, regional and synaptic specificity. *Eur J Neurosci* 2005;21:2671–80.
- [68] Stevens JR, Zharikova AD, Prokai L. Proteomic analysis of the synaptic plasma membrane fraction isolated from rat forebrain. *Brain Res Mol Brain Res* 2003;117:116–28.
- [69] Collins MO, Yu L, Coba MP, Husi H, Campuzano I, Blackstock WP, et al. Proteomic analysis of in vivo phosphorylated synaptic proteins. *J Biol Chem* 2005;280:5972–82.
- [70] Evans GJ, Barclay JW, Prescott GR, Jo SR, Burgoyne RD, Birnbaum MJ, et al. Protein kinase B/Akt is a novel cysteine string protein kinase that regulates exocytosis release kinetics and quantal size. *J Biol Chem* 2006;281:1564–72.
- [71] Chiang N, Hsiao YT, Yang HJ, Lin YC, Lu JC, Wang CT. Phosphomimetic mutation of cysteine string protein-alpha increases the rate of regulated exocytosis by modulating fusion pore dynamics in PC12 cells. *PLoS ONE* 2014;9:e99180.
- [72] Garcia-Junco-Clemente P, Cantero G, Gomez-Sanchez L, Linares-Clemente P, Martinez-Lopez JA, Lujan R, et al. Cysteine string protein-alpha prevents activity-dependent degeneration in GABAergic synapses. *J Neurosci* 2010;30:7377–91.
- [73] Ruiz R, Casanas JJ, Sudhof TC, Tabares L. Cysteine string protein-alpha is essential for the high calcium sensitivity of exocytosis in a vertebrate synapse. *Eur J Neurosci* 2008;27:3118–31.
- [74] Wishart TM, Rooney TM, Lamont DJ, Wright AK, Morton AJ, Jackson M, et al. Combining comparative proteomics and molecular genetics uncovers regulators of synaptic and axonal stability and degeneration in vivo. *PLoS Genet* 2012;8:e1002936.
- [75] Ruiz R, Biea IA, Tabares L. alpha-Synuclein A30P decreases neurodegeneration and increases synaptic vesicle release probability in CSPalpha-null mice. *Neuropharmacology* 2014;76 Pt A:106–17.
- [76] Wang Y, Yu Z, Ren H, Wang J, Wu J, Chen Y, et al. The synergistic effect between beta-amyloid and alpha-synuclein on the synapses dysfunction in hippocampal neurons. *J Chem Neuroanat* 2014;63C:1–5.
- [77] Takamori S, Holt M, Stenius K, Lemke EA, Grønborg M, Riedel D, et al. Molecular anatomy of a trafficking organelle. *Cell* 2006;127:831–46.
- [78] Wilhelm BG, Mandat S, Truckenbrodt S, Krohnert K, Schafer C, Rammner B, et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. *Science* 2014;344:1023–8.
- [79] Sharma M, Burre J, Sudhof TC. CSPalpha promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. *Nat Cell Biol* 2011;13:30–9.
- [80] Sharma M, Burre J, Bronk P, Zhang Y, Xu W, Sudhof TC. CSPalpha knock-out causes neurodegeneration by impairing SNAP-25 function. *EMBO J* 2012;31:829–41.
- [81] Burgoyne RD, Morgan A. Chaperoning the SNAREs: a role in preventing neurodegeneration. *Nat Cell Biol* 2011;13:8–9.
- [82] Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek R, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause

- autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. *Am J Hum Genet* 2011;89:241–52.
- [83] Benitez BA, Alvarado D, Cai Y, Mayo K, Chakraverty S, Norton J, et al. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. *PLoS ONE* 2011;6:e26741.
- [84] Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, et al. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. *PLOS ONE* 2012;7:e29729.
- [85] Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C, Barnabe A, et al. Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. *Clin Genet* 2013;83:571–5.
- [86] Haltia M. The neuronal ceroid-lipofuscinoses. *J Neuropathol Exp Neurol* 2003;62:1–13.
- [87] Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. *Biochim Biophys Acta* 2013;1832:1795–800.
- [88] Greaves J, Lemonidis K, Gorleku OA, Cruchaga C, Grefen C, Chamberlain LH. Palmitoylation-induced aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis. *J Biol Chem* 2012;287:37330–9.
- [89] Zhang YQ, Chandra SS. Oligomerization of cysteine string protein alpha mutants causing adult neuronal ceroid lipofuscinosis. *Biochim Biophys Acta* 2014;1842:2136–46.
- [90] Tiwari SS, Troakes MDOC, Shurovi BN, Engmann O, Noble W, Hortobagyi T, et al. Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer inverted question marks disease. *Mol Brain* 2015;8:6.
- [91] Davies MJ, Cooper M, Perry VH, O'Connor V. Reduced expression of the presynaptic co-chaperone cysteine string protein alpha (CSPalpha) does not exacerbate experimentally-induced ME7 prion disease. *Neurosci Lett* 2015;589:138–43.
- [92] Sharma M, Burre J, Sudhof TC. Proteasome inhibition alleviates SNARE-dependent neurodegeneration. *Sci Transl Med* 2012;4:147ra13.
- [93] Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. *Mech Ageing Dev* 2010;131:261–9.
- [94] Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. *Cell* 2012;148:421–33.
- [95] Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. *J Clin Invest* 2004;114:1624–34.
- [96] Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. *Proc Natl Acad Sci U S A* 2004;101:8786–90.
- [97] Evans GJ, Morgan A. Regulation of the exocytotic machinery by cAMP-dependent protein kinase: implications for presynaptic plasticity. *Biochem Soc Trans* 2003;31:824–7.
- [98] Nagy G, Reim K, Matti U, Brose N, Binz T, Rettig J, et al. Regulation of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25. *Neuron* 2004;41:417–29.
- [99] Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. *Nat Med* 2012;18:159–65.
- [100] Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. *Neurochem Int* 2009;54:111–8.